07.11.16
Headquarters: Bagsvaerd, Denmark
twitter.com/novonordisk
www.novonordisk.com
Headcount: 41,600
Year Established: 1989
Revenues: $15,801 (+22%)
Net Income: $5,104 (+32%)
R&D: $1,992 (-13%)
TOP SELLING DRUGS
In 2015 Novo Nordisk unveiled plans for a new $2 billion production facility in Clayton, NC, where construction has since begun. The facility will produce active pharmaceutical ingredients (APIs) for a range of the company’s current and future GLP-1 and insulin products. When fully operational in 2020, the site will take on production capacity for diabetes care products in the U.S. The new site is adjacent to Novo Nordisk’s existing 42,000 square-meter facility, which assembles and packages FlexPen and FlexTouch prefilled insulin devices for the U.S. market.
In other expansion news, Novo Nordisk said it is planning to invest more than €100 million in production facilities at its site in Chartres, France, in an effort to meet the increasing worldwide demand for its diabetes medicines. The new facilities will be built on Novo Nordisk’s existing 31,000 square-meter site in Chartres, which produces a range of the company’s insulin products as well as FlexPen, the world’s most widely used insulin injection device. The products are exported to more than 40 countries all over the world.
On the product approval front, the big news came when FDA approved Novo Nordisk’s weight management drug Saxenda (liraglutide 3mg). The drug is being touted as the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity. Saxenda is indicated as an adjunct to a reduced-calorie diet and exercise for chronic weight management in obese adults or who are overweight with at least one weight-related comorbidity such as type 2 diabetes and cardiovascular disease. Phase III trial data showed that Saxenda, in combination with a reduced-calorie diet and increased physical activity, resulted in significantly greater weight loss than diet and physical activity alone.
In R&D alliances, Novo Nordisk and Ablynx entered into a global exclusive collaboration and licensing agreement to discover and develop novel multi-specific Nanobody drug candidates for use in an undisclosed disease area, with an option to expand the agreement to include a second nanobody program. Ablynx received an upfront license fee of €5 million and up to €4 million in research funding during the initial three-year research term of the collaboration. If Novo Nordisk decides to exercise the option to the second program, the company will pay Ablynx an exercise fee of €4 million.
In another deal, XOMA Corporation licensed the global development and commercialization rights to its XMetA program of allosteric monoclonal antibodies that up-regulate the insulin receptor to Novo Nordisk. XOMA retains commercialization rights for rare disease indications. Novo Nordisk has an option to add these additional rights in rare diseases to its license. XOMA received $5 million in an upfront payment, and the agreement includes up to $290 million in additional milestones. XOMA is also eligible to receive tiered royalties on product sales.
twitter.com/novonordisk
www.novonordisk.com
Headcount: 41,600
Year Established: 1989
Revenues: $15,801 (+22%)
Net Income: $5,104 (+32%)
R&D: $1,992 (-13%)
TOP SELLING DRUGS
Drug | Indication | 2015 Sales | (+/-%) |
NovoRapid | diabetes | $3,033 | 7% |
Levemir | diabetes | $2,679 | 15% |
Victoza | diabetes | $2,639 | 20% |
Human | insulins diabetes | $1,644 | -2% |
NovoMix | diabetes | $1,631 | 1% |
Norditropin | HGH deficiency | $1,145 | 8% |
In 2015 Novo Nordisk unveiled plans for a new $2 billion production facility in Clayton, NC, where construction has since begun. The facility will produce active pharmaceutical ingredients (APIs) for a range of the company’s current and future GLP-1 and insulin products. When fully operational in 2020, the site will take on production capacity for diabetes care products in the U.S. The new site is adjacent to Novo Nordisk’s existing 42,000 square-meter facility, which assembles and packages FlexPen and FlexTouch prefilled insulin devices for the U.S. market.
In other expansion news, Novo Nordisk said it is planning to invest more than €100 million in production facilities at its site in Chartres, France, in an effort to meet the increasing worldwide demand for its diabetes medicines. The new facilities will be built on Novo Nordisk’s existing 31,000 square-meter site in Chartres, which produces a range of the company’s insulin products as well as FlexPen, the world’s most widely used insulin injection device. The products are exported to more than 40 countries all over the world.
On the product approval front, the big news came when FDA approved Novo Nordisk’s weight management drug Saxenda (liraglutide 3mg). The drug is being touted as the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity. Saxenda is indicated as an adjunct to a reduced-calorie diet and exercise for chronic weight management in obese adults or who are overweight with at least one weight-related comorbidity such as type 2 diabetes and cardiovascular disease. Phase III trial data showed that Saxenda, in combination with a reduced-calorie diet and increased physical activity, resulted in significantly greater weight loss than diet and physical activity alone.
In R&D alliances, Novo Nordisk and Ablynx entered into a global exclusive collaboration and licensing agreement to discover and develop novel multi-specific Nanobody drug candidates for use in an undisclosed disease area, with an option to expand the agreement to include a second nanobody program. Ablynx received an upfront license fee of €5 million and up to €4 million in research funding during the initial three-year research term of the collaboration. If Novo Nordisk decides to exercise the option to the second program, the company will pay Ablynx an exercise fee of €4 million.
In another deal, XOMA Corporation licensed the global development and commercialization rights to its XMetA program of allosteric monoclonal antibodies that up-regulate the insulin receptor to Novo Nordisk. XOMA retains commercialization rights for rare disease indications. Novo Nordisk has an option to add these additional rights in rare diseases to its license. XOMA received $5 million in an upfront payment, and the agreement includes up to $290 million in additional milestones. XOMA is also eligible to receive tiered royalties on product sales.